ClinicalTrials.gg
CompletedNCT00549198ASSERTUpdated Apr 12, 2011Results posted

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

A Phase 4 interventional study of Abacavir/lamivudine and efavirenz and Tenofovir/Emtricitabine and efavirenz in Infection, Human Immunodeficiency Virus I and HIV Infection, sponsored by GlaxoSmithKline. Completed at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.

Enrollment
9th of 50
392 · median 78
Started
2007
with 2 others
Phase 4
13 of 57
none open now
Registered
48th of 57
by date
Lead sponsor
5 of 57
GlaxoSmithKline

Among the 57 studies testing abacavir in HIV Infections, this one is the 9th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2007, is one of 13 in phase 4, and was the 48th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:

About abacavir

Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing abacavir in HIV Infections, or all of them as a file.
02

Study summary

Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens. However data from head-to-head randomized trials comparing these two FDCs as part of an initial regimen are not available at present. The long-term toxicity profiles of these regimens are of particular importance, as treatment of HIV is currently life-long and therefore, minimizing long-term toxicity and maximizing adherence and duration of regimen maintenance are critical therapy objectives.

The primary endpoint is estimated glomerular filtration rate (GFR), as measured by the modified diet in renal disease (MDRD) equation, a validated estimate of renal function.

Read the detailed description

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus I
  • HIV Infection

Browse trials for

Keywords

  • tenofovir
  • HIV
  • efavirenz
  • naive
  • lamivudine
  • abacavir
  • emtricitabine
  • renal
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 392 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is at least 18 years of age.
  • Subject is antiretroviral-naïve (defined as having no previous therapy with any NNRTI and 14 days of prior therapy with any other antiretroviral).
  • Subject has plasma -1 RNA 1,000 copies/mL at screening. This test may be repeated once within the 45-day screening window.
  • Subject is willing and able to understand and provide written prior to participation in this study.
  • A female is eligible to enter and participate in the study if she is of:

    1. Non- (i.e., physiologically incapable of becoming pregnant, including any female who is ); or,
    2. Child-bearing potential, has a negative pregnancy test at screen and agrees to one of the following methods of (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician):

Complete abstinence from intercourse from 2 weeks prior to administration of the products, throughout the study, and for at least 2 weeks after discontinuation of all study medications Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraception will not be considered adequate for inclusion into this study Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year.

Sterilization (female subject or male partner of female subject).

  • Prior to randomization, subjects must have been screened and be negative for the HLA-B*5701 allele. Test may be performed by local laboratory and results must be available for source document verification according to local practices.

Exclusion criteria

Exclusion Criteria:

  • Subject is in the initial acute phase of a CDC Clinical Category C infection at Baseline.
  • Subject is enrolled in one or more drug protocols, which may impact RNA suppression.
  • Subject is, in the opinion of the Investigator, unable to complete the study dosing period and protocol evaluations and assessments.
  • Subject is either pregnant or breastfeeding.
  • Subject suffers from a serious medical condition, which in the opinion of the Investigator would compromise the safety of the subject.
  • Subject has a history of inflammatory bowel disease or other gastrointestinal dysfunction.
  • Subject has any acute laboratory abnormality at screening.
  • Subject has an estimated within the screening period \<50mL/min via the Cockcroft-Gault method.
  • (ALT) >5 times the .
  • Subjects with a history of thyroid disease, hyperparathyroid disease, chronic hyper or hypocalcemia, vitamin D deficiency, or receiving thyroid hormone or parathyroid hormone replacement within 28 days prior to screening.
  • Subjects with a history of systemic inflammatory arthritis.
  • Subjects who are positive at screening.
  • Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents.
  • Subject has received treatment with an HIV-1 immunotherapeutic vaccine or any agents with documented activity against HIV-1 in vitro within 28 days prior to Screening, or an anticipated need during the study.
  • Subjects who require treatment with any of the following medications within 28 days of commencement of investigational product, or an anticipated need during the study:
  • Medications with significant drug-drug interactions with efavirenz:voriconazole, terfenadine, astemizole, cisapride, ergot alkaloids (dihydroergotamine, ergonovine, ergotamine, methylergonovine), midazolam, triazolam, St. John's wort, carbamazepine, phenytoin, phenobarbital, rifampin, pimozide, bepridil
  • Medications which may impact on bone mineral density: oral or systemic , anticonvulsants, heparin, warfarin, cyclosporine, bisphosphonates, calcitonin, parathyroid hormone, Vitamin D supplements and analogues, Calcium supplements, oestrogen or progesterone replacement (oral hormonal permitted), raloxifene, tamoxifen, testosterone or anabolic steroid replacement/supplements.
  • Systemic interleukins or interferons
  • Subject has a history of allergy to any of the protocol-specified medications or any therein.
  • Subject has evidence of genotypic resistance at screening (according to central lab interpretation) or prior documented evidence of genotypic and/or phenotypic (above threshold for reduced susceptibility) resistance to any of the following drugs: efavirenz, abacavir, lamivudine, tenofovir, emtricitabine.
  • Subjects who are unsuitable for DEXA scanning should be excluded, including 1) Less than three vertebra in the range of L1 to L4 that are suitable for BMD measurement by DEXA, or 2) Bilateral hip replacement.
  • The subject has previously participated in an experimental drug and/or vaccine trial(s) within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study.
  • The subject will participate simultaneously in another clinical study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    ABC/3TC + EFV

    Drug: Abacavir/lamivudine and efavirenz

  • Active comparator
    TDF/FTC + EFV

    Drug: Tenofovir/Emtricitabine and efavirenz

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48

    Change from baseline was calculated as the Week 48 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine; BMI, body mass index.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24

    Change from baseline was calculated as the Week 24 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine.

    Time frame: Baseline, Week 24

  2. Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96

    Change from baseline was calculated as the Week 96 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^s, meters squared; Scr, serum creatinine.

    Time frame: Baseline, Week 96

  3. Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24

    Change from baseline was calculated as the Week 24 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram; CG, Cockcroft-Gault.

    Time frame: Baseline, Week 24

  4. Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48

    Change from baseline was calculated as the Week 48 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.

    Time frame: Baseline, Week 48

  5. Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96

    Change from baseline was calculated as the Week 96 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.

    Time frame: Baseline, Week 96

  6. Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24

    mL, milliliter; min, minute; m\^2, meters squared

    Time frame: Baseline, Week 24

  7. Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48

    mL, milliliter; min, minute; m\^2, meters squared

    Time frame: Baseline, Week 48

  8. Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96

    mL, milliliter; min, minute; m\^2, meters squared

    Time frame: Baseline, Week 96

  9. Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24

    Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

    Time frame: Baseline, Week 24

  10. Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48

    Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

    Time frame: Baseline, Week 48

  11. Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96

    Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

    Time frame: Baseline, Week 96

  12. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24

    BMD is a measure (grams \[g\] per centimeters cubed \[cm\^3\]) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 24

  13. Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24

    BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 24

  14. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48

    BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 48

  15. Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48

    BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 48

  16. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96

    BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 96

  17. Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96

    BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

    Time frame: Baseline, Week 96

  18. Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24

    BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

    Time frame: Baseline, Week 24

  19. Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48

    BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

    Time frame: Baseline, Week 48

  20. Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96

    BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

    Time frame: Baseline, Week 96

  21. Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24

    The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

    Time frame: Week 24

  22. Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48

    The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

    Time frame: Week 48

  23. Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96

    The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

    Time frame: Week 96

  24. Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24

    An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

    Time frame: Baseline to Week 24

  25. Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48

    An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

    Time frame: Baseline to Week 48

  26. Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96

    An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

    Time frame: Baseline to Week 96

  27. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

    Time frame: Baseline, Week 24

  28. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

    Time frame: Baseline, Week 48

  29. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

    Time frame: Baseline, Week 96

  30. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

    Time frame: Baseline, Week 24

  31. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

    Time frame: Baseline, Week 48

  32. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

    Time frame: Baseline, Week 96

  33. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

    Time frame: Baseline, Week 24

  34. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

    Time frame: Baseline, Week 48

  35. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

    Time frame: Baseline, Week 96

  36. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.

    Time frame: Baseline, Week 24

  37. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.

    Time frame: Baseline, Week 48

  38. Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96

    Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\>200 mg/dL, borderline high; 200-\<500 mg/dL, high;\>= 500 mg/dL, very high.

    Time frame: Baseline, Week 96

  39. Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24

    The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.

    Time frame: Week 24

  40. Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48

    The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.

    Time frame: Week 48

  41. Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96

    The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug therapy.

    Time frame: Week 96

  42. Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24

    HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

    Time frame: Week 24

  43. Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48

    HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

    Time frame: Week 48

  44. Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96

    HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

    Time frame: Week 96

  45. Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24

    CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

    Time frame: Baseline, Week 24

  46. Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48

    CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

    Time frame: Baseline, Week 48

  47. Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96

    CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

    Time frame: Baseline, Week 96

  48. Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96

    Viral resistance was measured using blood samples collected from participants throughout the study. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. Virological failure was defined as any one of: participant does not achieve a 1 log10 copies (cop)/mL decrease in plasma HIV-1 RNA by Week (Wk) 4, or has two consecutive plasma HIV-1 RNA measures \>=400 cop/mL separated by at least 2-4 wk after being previously \<=400 cop/mL on/after Wk 4, or has two consecutive plasma HIV-1 RNA measures \>400 cop/mL separated by at least 2-4 wk on/after Wk 24.

    Time frame: Week 96

  49. Number of Participants Who Indicated "Yes" or "No" to the Question of Whether Unplanned Healthcare Resources Were Utilized

    Participants were asked at each visit whether or not they utilized unplanned healthcare resources.

    Time frame: Baseline to Week 96

Other outcomes

  1. Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96

    Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline albumin value by the urine creatinine value. Albumin is measured in milligrams per millimole (mg/mmol).

    Time frame: Baseline, Week 96

  2. Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96

    Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline B2M value by the urine creatinine value. B2M, beta 2 microglobulin (measured in mg/mmol).

    Time frame: Baseline, Week 96

  3. Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96

    Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline NAG value by the urine creatinine value. NAG, N-acetyl-B-glucosaminidase (measured in micromoles per hour per millimole \[umol/h/mmol\]).

    Time frame: Baseline, Week 96

  4. Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96

    Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline RBP value by the urine creatinine value. RBP, retinol binding protein (measured in micrograms per millimole \[ug/mmol\]).

    Time frame: Baseline, Week 96

  5. Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96

    P1NP is a bone biomarker that was analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

    Time frame: Baseline, Week 96

  6. Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96

    Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

    Time frame: Baseline, Week 96

  7. Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96

    Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

    Time frame: Baseline, Week 96

  8. Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96

    Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

    Time frame: Baseline, Week 96

08

Results

Posted Oct 15, 2010

Participant flow

Participant flow — Overall Study
MilestoneABC/3TC FDCTDF/FTC FDC
Started195197
Completed115134
Not completed8063
Withdrew: Adverse event2826
Withdrew: Insufficient viral load response42
Withdrew: Protocol-defined virological failure70
Withdrew: Non-compliance24
Withdrew: Lost to follow-up78
Withdrew: Treatment eligibility criteria not met30
Withdrew: Protocol violation72
Withdrew: Investigator decision43
Withdrew: Withdrawal by subject77
Withdrew: Disease progression10
Withdrew: Participant moved20
Withdrew: Participant not able to perform week 9610
Withdrew: Participant moved.week 96 visit, no scan10
Withdrew: Prohibited medication12
Withdrew: Participant planning pregnancy10
Withdrew: Participant overweight, no scan possible10
Withdrew: No scan facilities02
Withdrew: Pregnancy03
Withdrew: Not exposed to study drug34

Outcome measures

PrimaryMean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48

Change from baseline was calculated as the Week 48 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine; BMI, body mass index.

Time frame:
Baseline, Week 48
Reported as:
Mean · milliliters per minute (mL/min)/1.73 m^2
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48
milliliters per minute (mL/min)/1.73 m^2ABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 480.22 ± 0.8901.18 ± 0.828
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.435 (The model includes the following covariates: treatment, visit, baseline GFR by MDRD, baseline BMI, race group, treatment\*visit, baseline GFR by MDRD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryMean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24

Change from baseline was calculated as the Week 24 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min/1.73m^2
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24
mL/min/1.73m^2ABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 242.78 ± 0.8840.43 ± 0.842
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.057 (The model includes the following covariates: treatment, visit, baseline GFR by MDRD, baseline BMI, race group, age group, treatment\*visit, baseline GFR by MDRD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryMean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96

Change from baseline was calculated as the Week 96 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^s, meters squared; Scr, serum creatinine.

Time frame:
Baseline, Week 96
Reported as:
Mean · mL/min/1.73m^2
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96
mL/min/1.73m^2ABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 961.48 ± 1.022-1.15 ± 0.944
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.060 (The model includes the following covariates: treatment, visit, baseline GFR by MDRD, baseline BMI, race group, treatment\*visit, baseline GFR by MDRD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryMean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24

Change from baseline was calculated as the Week 24 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram; CG, Cockcroft-Gault.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24
mL/minABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 244.27 ± 0.9442.54 ± 0.897
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.186 (The model includes the following covariates: treatment, visit, baseline GFR by CG, baseline BMI, race group, age group, hypertension, treatment\*visit, baseline GFR by CG\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryMean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48

Change from baseline was calculated as the Week 48 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.

Time frame:
Baseline, Week 48
Reported as:
Mean · mL/min
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48
mL/minABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 482.66 ± 1.0053.80 ± 0.933
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.413 (The model includes the following covariates: treatment, visit, baseline GFR by CG, baseline BMI, race group, age group, hypertension, treatment\*visit, baseline GFR by CG\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryMean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96

Change from baseline was calculated as the Week 96 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.

Time frame:
Baseline, Week 96
Reported as:
Mean · mL/min
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96
mL/minABC/3TC FDCTDF/FTC FDC
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 964.37 ± 1.2282.68 ± 1.133
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.315 (The model includes the following covariates: treatment, visit, baseline GFR by CG, baseline BMI, race group, baseline CD4, treatment\*visit, baseline GFR by CG\*visit, baseline BMI\*visit and baseline CD4\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryNumber of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24

mL, milliliter; min, minute; m\^2, meters squared

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24
participantsABC/3TC FDCTDF/FTC FDC
>=10 mL/min, MDRD1626
>=10 mL/min, Cockcroft-Gault1620
>=20 mL/min, MDRD46
>=20 mL/min, Cockcroft-Gault34
>=10%, MDRD1524
>=10%, Cockcroft-Gault1017
>=20%, MDRD23
>=20%, Cockcroft-Gault23
SecondaryNumber of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48

mL, milliliter; min, minute; m\^2, meters squared

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48
participantsABC/3TC FDCTDF/FTC FDC
>=10 mL/min, MDRD2321
>=10 mL/min, Cockcroft-Gault1514
>=20 mL/min, MDRD43
>=20 mL/min, Cockcroft-Gault42
>=10%, MDRD2121
>=10%, Cockcroft-Gault119
>=20%, MDRD42
>=20%, Cockcroft-Gault30
SecondaryNumber of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96

mL, milliliter; min, minute; m\^2, meters squared

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96
participantsABC/3TC FDCTDF/FTC FDC
>=10 mL/min, MDRD1538
>=10 mL/min, Cockcroft-Gault1119
>=20 mL/min, MDRD47
>=20 mL/min, Cockcroft-Gault45
>=10%, MDRD1527
>=10%, Cockcroft-Gault1216
>=20%, MDRD36
>=20%, Cockcroft-Gault34
SecondaryNumber of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24

Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Normal97114
Stage 11115
Stage 255
Stage 311
Stage 400
Stage 500
SecondaryNumber of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48

Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Missing1219
Normal90106
Stage 175
Stage 233
Stage 300
Stage 400
Stage 500
SecondaryNumber of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96

Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Missing1118
Normal7583
Stage 134
Stage 244
Stage 300
Stage 400
Stage 500
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24

BMD is a measure (grams \[g\] per centimeters cubed \[cm\^3\]) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24-2.12 ± 0.0011-3.30 ± 0.0011
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = <0.001 (The model includes the following covariates: treatment, visit, baseline spine BMD, baseline BMI, race group, age group, hypertension, treatment\*visit, baseline spine BMD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24

BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24-1.19 ± 0.0007-2.73 ± 0.0007
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = <0.001 (The model includes the following covariates: treatment, visit, baseline hip BMD, baseline BMI, race group, risk factor, country group, treatment\*visit, baseline hip BMD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48

BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48-1.59 ± 0.0013-2.41 ± 0.0012
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.036 (The model includes the following covariates: treatment, visit, baseline spine BMD, baseline BMI, race group, age group, treatment\*visit, baseline spine BMD\*visit and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48

BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48-1.90 ± 0.0010-3.56 ± 0.0009
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = <0.001 (The model includes the following covariates: treatment, visit, baseline hip BMD, baseline BMI, race group, risk factor, prohibited medication, previous fracture, treatment\*visit, baseline hip BMD\*visit and baseline BMI\*visit.)Correlation matrix for within-subject errors is unstructured.
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96

BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96-0.87 ± 0.0017-1.70 ± 0.0015
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = 0.112 (The model includes the following covariates: treatment, visit, baseline spine BMD, baseline BMI, race group, age group, treatment\*visit, baseline spine BMD\*visit and baseline BMI\*visit.)correlation matrix for within-subject errors is unstructured.
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96

BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.

Time frame:
Baseline, Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
percent changeABC/3TC FDCTDF/FTC FDC
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96-2.17 ± 0.0013-3.55 ± 0.0012
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · Mixed Models Analysis · p = <0.001 (The model includes the following covariates: treatment, visit, baseline hip BMD, baseline BMI, race group, risk factor, prohibited medication, previous fracture, treatment\*visit, baseline hip BMD\*visit, and baseline BMI\*visit.)The correlation matrix for within-subject errors is unstructured.
SecondaryNumber of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24

BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24
participantsABC/3TC FDCTDF/FTC FDC
>=2%, spine, n=142, 16573115
>=6%, spine, n=142, 1651017
>=2%, hip, n=137, 1603893
>=6%, hip, n=137, 16016
SecondaryNumber of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48

BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48
participantsABC/3TC FDCTDF/FTC FDC
>=2%, spine, n=125, 1415184
>=6%, spine, n=125, 141513
>=2%, hip, n=119, 14054111
>=6%, hip, n=119, 140317
SecondaryNumber of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96

BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96
participantsABC/3TC FDCTDF/FTC FDC
>=2%, spine, n=59, 792139
>=6%, spine, n=59, 7938
>=2%, hip, n=58, 763352
>=6%, hip, n=58, 76113
SecondaryNumber of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24

The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Osteopenia, spine, n=147, 1734168
Osteporosis, spine, n=147, 173169
Osteopenia, hip, n=149, 1703854
Osteoporosis, hip, n=149, 17041
SecondaryNumber of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48

The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Osteopenia, spine, n=132, 1474157
Osteporosis, spine, n=132, 147155
Osteopenia, hip, n=130, 1473750
Osteoporosis, hip, n=130, 14740
SecondaryNumber of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96

The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Osteopenia, spine, n=64, 822134
Osteporosis, spine, n=64, 8253
Osteopenia, hip, n=65, 802031
Osteoporosis, hip, n=65, 8000
SecondaryNumber of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24

An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

Time frame:
Baseline to Week 24
Reported as:
Number · participants
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24
participantsABC/3TC FDCTDF/FTC FDC
Any event2614
Drug hypersensitivity111
Rash23
Dizziness02
Hypersensitivity30
Drug eruption11
SecondaryNumber of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48

An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

Time frame:
Baseline to Week 48
Reported as:
Number · participants
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48
participantsABC/3TC FDCTDF/FTC FDC
Any event2921
Drug hypersensitivity111
Bone density decreased02
Rash23
Dizziness13
Hypersensitivity30
Drug eruption11
SecondaryNumber of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96

An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96
participantsABC/3TC FDCTDF/FTC FDC
Any event3328
Drug hypersensitivity111
Bone density decreased08
Rash23
Dizziness13
Hypersensitivity30
Abnormal dreams30
Drug eruption11
Depression02
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Desirable to desirable54104
Desirable to borderline high4729
Desirable to high329
Borderline high to desirable13
Borderline high to borderline high29
Borderline high to high106
High to desirable00
High to borderline high00
High to high32
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Desirable to desirable4696
Desirable to borderline high5237
Desirable to high369
Borderline high to desirable11
Borderline high to borderline high29
Borderline high to high108
High to desirable00
High to borderline high00
High to high32
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Desirable to desirable3986
Desirable to borderline high4947
Desirable to high4610
Borderline high to desirable11
Borderline high to borderline high29
Borderline high to high108
High to desirable00
High to borderline high00
High to high32
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Optimal to optimal2246
Optimal to near or above optimal4143
Optimal to borderline high2211
Optimal to high61
Optimal to very high10
Near or above optimal to optimal05
Near or above optimal to near or above optimal622
Near or above optimal to borderline high1711
Near or above optimal to high125
Near or above optimal to very high41
Borderline high to optimal00
Borderline high to near or above optimal16
Borderline high to borderline high23
Borderline high to high43
Borderline high to very high32
High to optimal00
High to near or above optimal00
High to borderline high00
High to high11
High to very high00
Very high to optimal00
Very high to near or above optimal00
Very high to borderline high10
Very high to high00
Very high to very high11
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Optimal to optimal2042
Optimal to near or above optimal3846
Optimal to borderline high2712
Optimal to high81
Optimal to very high10
Near or above optimal to optimal03
Near or above optimal to near or above optimal421
Near or above optimal to borderline high1913
Near or above optimal to high126
Near or above optimal to very high41
Borderline high to optimal00
Borderline high to near or above optimal13
Borderline high to borderline high25
Borderline high to high34
Borderline high to very high42
High to optimal00
High to near or above optimal00
High to borderline high00
High to high11
High to very high00
Very high to optimal00
Very high to near or above optimal00
Very high to borderline high10
Very high to high00
Very high to very high11
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Optimal to optimal1837
Optimal to near or above optimal3546
Optimal to borderline high2917
Optimal to high91
Optimal to very high30
Near or above optimal to optimal01
Near or above optimal to near or above optimal419
Near or above optimal to borderline high1716
Near or above optimal to high127
Near or above optimal to very high62
Borderline high to optimal00
Borderline high to near or above optimal13
Borderline high to borderline high25
Borderline high to high33
Borderline high to very high43
High to optimal00
High to near or above optimal00
High to borderline high00
High to high11
High to very high00
Very high to optimal00
Very high to near or above optimal00
Very high to borderline high10
Very high to high00
Very high to very high11
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Low to low1936
Low to normal7266
Low to high109
Normal to low01
Normal to normal1230
Normal to high2612
High to low00
High to normal03
High to high105
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Low to low1728
Low to normal6773
Low to high1810
Normal to low00
Normal to normal1123
Normal to high2720
High to low00
High to normal03
High to high105
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Low to low1123
Low to normal6675
Low to high2513
Normal to low00
Normal to normal817
Normal to high3027
High to low00
High to normal01
High to high107
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Normal to normal6378
Normal to borderline high2119
Normal to high239
Normal to very high00
Borderline high to normal57
Borderline high to borderline high510
Borderline high to high915
Borderline high to very high00
High to normal26
High to borderline high53
High to high1215
High to very high30
Very high to normal00
Very high to borderline high00
Very high to high01
Very high to very high10
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.

Time frame:
Baseline, Week 48
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Normal to normal5570
Normal to borderline high2223
Normal to high3012
Normal to very high01
Borderline high to normal46
Borderline high to borderline high57
Borderline high to high1119
Borderline high to very high00
High to normal25
High to borderline high43
High to high1215
High to very high40
Very high to normal00
Very high to borderline high00
Very high to high01
Very high to very high10
SecondaryNumber of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96

Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\>200 mg/dL, borderline high; 200-\<500 mg/dL, high;\>= 500 mg/dL, very high.

Time frame:
Baseline, Week 96
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Normal to normal4755
Normal to borderline high2531
Normal to high3420
Normal to very high11
Borderline high to normal45
Borderline high to borderline high48
Borderline high to high1119
Borderline high to very high10
High to normal25
High to borderline high42
High to high1116
High to very high50
Very high to normal00
Very high to borderline high00
Very high to high01
Very high to very high10
SecondaryNumber of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24

The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24
participantsABC/3TC FDCTDF/FTC FDC
Cholesterol, Grade 361
Cholesterol, Grade 400
LDL cholesterol, Grade 383
LDL cholesterol, Grade 400
Non-HDL cholesterol, Grade 3195
Non-HDL cholesterol, Grade 400
Triglycerides, Grade 320
Triglycerides, Grade 400
Alanine aminotransferase, Grade 313
Alanine aminotransferase, Grade 411
Aspartate aminotransferase, Grade 310
Aspartate aminotransferase, Grade 412
Alkaline phosphatase, Grade 301
Alkaline phosphatase, Grade 400
Creatinine kinase, Grade 301
Creatinine kinase, Grade 411
Phosphorus inorganic, Grade 311
Phosphorus inorganic, Grade 400
Lipase, Grade 331
Lipase, Grade 420
Hyperkalaemia, Grade 300
Hyperkalaemia, Grade 411
Glomerular filtration rate, MDRD, Grade 311
Glomerular filtration rate, MDRD, Grade 400
Total neutrophils, Grade 310
Total neutrophils, Grade 412
Thrombocytopenia, Grade 310
Thrombocytopenia, Grade 400
SecondaryNumber of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48

The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48
participantsABC/3TC FDCTDF/FTC FDC
Cholesterol, Grade 371
Cholesterol, Grade 400
LDL cholesterol, Grade 393
LDL cholesterol, Grade 400
Non-HDL cholesterol, Grade 3206
Non-HDL cholesterol, Grade 400
Triglycerides, Grade 330
Triglycerides, Grade 400
Alanine aminotransferase, Grade 324
Alanine aminotransferase, Grade 421
Aspartate aminotransferase, Grade 320
Aspartate aminotransferase, Grade 422
Alkaline phosphatase, Grade 301
Alkaline phosphatase, Grade 400
Total bilirubin Grade 310
Total bilirubin, Grade 400
Creatinine kinase, Grade 302
Creatinine kinase, Grade 411
Phosphorus inorganic, Grade 331
Phosphorus inorganic, Grade 400
Lipase, Grade 351
Lipase, Grade 420
Hyperkalaemia, Grade 300
Hyperkalaemia, Grade 422
Glomerular filtration rate, MDRD, Grade 311
Glomerular filtration rate, MDRD, Grade 400
Total neutrophils, Grade 320
Total neutrophils, Grade 432
Thrombocytopenia, Grade 410
Thrombocytopenia, Grade 400
SecondaryNumber of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96

The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug therapy.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Cholesterol, Grade 391
Cholesterol, Grade 400
LDL cholesterol, Grade 3135
LDL cholesterol, Grade 400
Non-HDL cholesterol, Grade 3225
Non-HDL cholesterol, Grade 400
Triglycerides, Grade 320
Triglycerides, Grade 410
Alanine aminotransferase, Grade 324
Alanine aminotransferase, Grade 421
Aspartate aminotransferase, Grade 321
Aspartate aminotransferase, Grade 422
Alkaline phosphatase, Grade 301
Alkaline phosphatase, Grade 400
Total bilirubin, Grade 310
Total bilirubin, Grade 400
Creatinine kinase, Grade 302
Creatinine kinase, Grade 412
Phosphorus inorganic, Grade 343
Phosphorus inorganic, Grade 400
Lipase, Grade 362
Lipase, Grade 442
Hyperkalaemia, Grade 300
Hyperkalaemia, Grade 420
Glomerular filtration rate, MDRD, Grade 311
Glomerular filtration rate, MDRD, Grade 400
Total neutrophils, Grade 331
Total neutrophils, Grade 453
Thrombocytopenia, Grade 310
Thrombocytopenia, Grade 400
SecondaryNumber of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24

HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24
participantsABC/3TC FDCTDF/FTC FDC
<50 copies/mL126144
<400 copies/mL147168
SecondaryNumber of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48

HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48
participantsABC/3TC FDCTDF/FTC FDC
<50 copies/mL121145
<400 copies/mL130151
SecondaryNumber of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96

HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96
participantsABC/3TC FDCTDF/FTC FDC
<50 copies/mL98113
<400 copies/mL110126
SecondaryChange From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24

CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

Time frame:
Baseline, Week 24
Reported as:
Median · cells/millimeters cubed (mm^3)
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24
cells/millimeters cubed (mm^3)ABC/3TC FDCTDF/FTC FDC
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24110.0 (50.0 to 180.0)100.0 (45.0 to 150.0)
SecondaryChange From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48

CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

Time frame:
Baseline, Week 48
Reported as:
Median · cells/mm^3
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48
cells/mm^3ABC/3TC FDCTDF/FTC FDC
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48150.0 (95.0 to 270.0)150.0 (80.0 to 215.0)
SecondaryChange From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96

CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.

Time frame:
Baseline, Week 96
Reported as:
Median · cells/mm^3
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96
cells/mm^3ABC/3TC FDCTDF/FTC FDC
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96235.0 (130.0 to 390.0)220.0 (150.0 to 315.0)
SecondaryNumber of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96

Viral resistance was measured using blood samples collected from participants throughout the study. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. Virological failure was defined as any one of: participant does not achieve a 1 log10 copies (cop)/mL decrease in plasma HIV-1 RNA by Week (Wk) 4, or has two consecutive plasma HIV-1 RNA measures \>=400 cop/mL separated by at least 2-4 wk after being previously \<=400 cop/mL on/after Wk 4, or has two consecutive plasma HIV-1 RNA measures \>400 cop/mL separated by at least 2-4 wk on/after Wk 24.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96
participantsABC/3TC FDCTDF/FTC FDC
Any treatment-emergent mutation40
NRTI40
NNRTI20
SecondaryNumber of Participants Who Indicated "Yes" or "No" to the Question of Whether Unplanned Healthcare Resources Were Utilized

Participants were asked at each visit whether or not they utilized unplanned healthcare resources.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants Who Indicated "Yes" or "No" to the Question of Whether Unplanned Healthcare Resources Were Utilized
participantsABC/3TC FDCTDF/FTC FDC
Week 4, Yes, n=178, 1836049
Week 4, No, n=178, 183118134
Week 12, Yes, n=162, 1775647
Week 12, No, n=162, 177106130
Week 24, Yes, n=156, 1737059
Week 24, No, n=156, 17386114
Week 36, Yes, n=148, 1694850
Week 36, No, n=148, 169100119
Week 48, Yes, n=137, 1614436
Week 48, No, n=137, 16193125
Week 60, Yes, n=129, 1484744
Week 60, No, n=129, 14882104
Week 72, Yes, n=126, 1394840
Week 72, No, n=126, 1397899
Week 84, Yes, n=121, 1363424
Week 84, No, n=121, 13687108
Week 96, Yes, n=113, 1353017
Week 96, No, n=113, 13583118
Other pre-specifiedExploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96

Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline albumin value by the urine creatinine value. Albumin is measured in milligrams per millimole (mg/mmol).

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ratio
Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96
ratioABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 960.872 (0.716 to 1.062)0.973 (0.806 to 1.174)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = 0.3025 (The model includes the following covariates: treatment, age, baseline biomarker value, and gender.)Estimates are calculated from an ANOVA model. Parameters are analyzed based on log transformed data.
Other pre-specifiedExploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96

Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline B2M value by the urine creatinine value. B2M, beta 2 microglobulin (measured in mg/mmol).

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ratio
Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96
ratioABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 960.542 (0.370 to 0.792)0.984 (0.684 to 1.416)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = <0.0001 (The model includes the following covariates: treatment, age, baseline biomarker value, baseline CD4, and gender.)Estimates are calculated from an ANOVA model. Parameters are analyzed based on log transformed data.
Other pre-specifiedExploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96

Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline NAG value by the urine creatinine value. NAG, N-acetyl-B-glucosaminidase (measured in micromoles per hour per millimole \[umol/h/mmol\]).

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ratio
Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96
ratioABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 960.868 (0.774 to 0.974)0.939 (0.844 to 1.044)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = 0.3323 (The model includes the following covariates: treatment, age, and baseline biomarker value.)Estimates are calculated from an ANOVA model. Parameters are analyzed based on log transformed data.
Other pre-specifiedExploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96

Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline RBP value by the urine creatinine value. RBP, retinol binding protein (measured in micrograms per millimole \[ug/mmol\]).

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ratio
Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96
ratioABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 961.099 (0.882 to 1.369)1.550 (1.247 to 1.927)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = <0.0001 (The model includes the following covariates: treatment, baseline biomarker value, baseline CD4, and gender.)Estimates are calculated from an ANOVA model. Parameters are analyzed based on log transformed data.
Other pre-specifiedExploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96

P1NP is a bone biomarker that was analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · micrograms per Liter (ug/L)
Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96
micrograms per Liter (ug/L)ABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 961.2 (1.1 to 1.2)1.4 (1.3 to 1.5)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = <0.0001 (The model includes the following covariates: treatment, age, and baseline biomarker value.)Estimates are calculated from ana ANOVA model. Parameters are analyzed based on log transformed data.
Other pre-specifiedExploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96

Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · nanograms per Liter (ng/L)
Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96
nanograms per Liter (ng/L)ABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 9689.9 (25.1 to 154.7)203.6 (143.3 to 264.0)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = 0.0019 (The model includes the following covariates: treatment, baseline biomarker value, and gender.)Estimates are calculated from an ANOVA model.
Other pre-specifiedExploratory Analysis of Change From Baseline in Osteocalcin at Week 96

Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ug/L
Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96
ug/LABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Osteocalcin at Week 963.01 (0.87 to 5.14)5.79 (3.68 to 7.90)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = 0.0019 (The model includes the following covariates: treatment, age, baseline biomarker value, and baseline CD4.)Estimates are calculated from an ANOVA model.
Other pre-specifiedExploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96

Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.

Time frame:
Baseline, Week 96
Reported as:
Geometric mean · ug/L
Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96
ug/LABC/3TC FDCTDF/FTC FDC
Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 961.111 (-0.426 to 2.649)2.542 (1.028 to 4.056)
Statistical analysis
  • ABC/3TC FDC vs TDF/FTC FDC · ANOVA · p = 0.0266 (The model includes the following covariates: treatment, baseline biomarker value, and baseline CD4.)Estimates are calculated from an ANOVA model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABC/3TC FDC—31/192 (16.1%)172/192 (89.6%)
TDF/FTC FDC—20/193 (10.4%)175/193 (90.7%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventABC/3TC FDCTDF/FTC FDC
Drug hypersensitivityImmune system disorders5/1921/193
PneumoniaInfections and infestations5/1921/193
HypersensitivityImmune system disorders3/1920/193
GastroenteritisInfections and infestations2/1920/193
Immune reconstitution syndromeImmune system disorders2/1920/193
Lower respiratory tract infectionInfections and infestations1/1921/193
Pulmonary tuberculosisInfections and infestations1/1921/193
ErysipelasInfections and infestations1/1920/193
Eye infection toxoplasmalInfections and infestations1/1920/193
Herpes ZosterInfections and infestations1/1920/193
Most frequent other events
Showing 10 of 16
Most frequent other events
EventABC/3TC FDCTDF/FTC FDC
DizzinessNervous system disorders48/19248/193
NasopharyngitisInfections and infestations39/19236/193
DiarrhoeaGastrointestinal disorders36/19227/193
HeadacheNervous system disorders17/19229/193
Abnormal dreamsPsychiatric disorders23/19222/193
InsomniaPsychiatric disorders21/19218/193
RashSkin and subcutaneous tissue disorders18/19220/193
NauseaGastrointestinal disorders17/19216/193
CoughRespiratory, thoracic and mediastinal disorders17/19213/193
Sleep disorderPsychiatric disorders14/19216/193

Baseline characteristics

Age Continuous
Age Continuous(Years)ABC/3TC FDCTDF/FTC FDCTotal
Median38.0 (19 to 70)36.0 (18 to 66)37.0 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)ABC/3TC FDCTDF/FTC FDCTotal
Female334073
Male159153312
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ABC/3TC FDCTDF/FTC FDCTotal
African American/African Heritage263056
American Indian or Alaska Native11718
Asian257
White153151304
09

Study locations

68 sites
  • GSK Investigational Site
    Innsbruck, A-6020, Austria
  • GSK Investigational Site
    Salzburg, A-5020, Austria
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Vienna, A-1140, Austria
  • GSK Investigational Site
    Brugge, 8000, Belgium
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Charleroi, 6000, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Aalborg, DK-9000, Denmark
  • GSK Investigational Site
    Aarhus N, 8200, Denmark
  • GSK Investigational Site
    Hvidovre, DK-2650, Denmark
  • GSK Investigational Site
    Koebenhavn, DK-2100, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Garches, 92380, France
  • GSK Investigational Site
    Levallois-Perret, 92300, France
  • GSK Investigational Site
    Saint Denis Cedex 01, 93205, France
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69115, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80335, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40237, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04170, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Dublin, 7, Ireland
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Ferrara, Emilia-Romagna 44100, Italy
  • GSK Investigational Site
    Modena, Emilia-Romagna 41100, Italy
  • GSK Investigational Site
    Rimini, Emilia-Romagna 47900, Italy
  • GSK Investigational Site
    Roma, Lazio 00149, Italy
  • GSK Investigational Site
    Legnano (MI, Lombardia 20025, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Torino, Piemonte 10149, Italy
  • GSK Investigational Site
    Riga, LV 1006, Latvia
  • GSK Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • GSK Investigational Site
    Den Haag, 2512 VA, Netherlands
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Rotterdam, 3078 HT, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
  • GSK Investigational Site
    Amadora, 2720-276, Portugal
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Valencia, 46015, Spain
  • GSK Investigational Site
    Basel, 4031, Switzerland
  • GSK Investigational Site
    Bern, 3010, Switzerland
  • GSK Investigational Site
    Lausanne, 1011, Switzerland
  • GSK Investigational Site
    St Gallen, 9007, Switzerland
  • GSK Investigational Site
    Zuerich, 8091, Switzerland
  • GSK Investigational Site
    Zurich, 8038, Switzerland
  • GSK Investigational Site
    Manchester, Lancashire M8 5RB, United Kingdom
  • GSK Investigational Site
    Woolwich, London, London SE18 4QH, United Kingdom
  • GSK Investigational Site
    Edinburgh, Midlothian EH4 2XU, United Kingdom
  • GSK Investigational Site
    Brighton, Sussex East BN2 1ES, United Kingdom
  • GSK Investigational Site
    Birmingham, B4 6DH, United Kingdom
  • GSK Investigational Site
    Birmingham, WS2 9PS, United Kingdom
  • GSK Investigational Site
    Farnworth, Bolton, BL4 0JR, United Kingdom
  • GSK Investigational Site
    Gloucester, GL1 3NN, United Kingdom
  • GSK Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
  • GSK Investigational Site
    London, N18 1QX, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    London, SW10 9TH, United Kingdom
  • GSK Investigational Site
    London, SW17 0QT, United Kingdom
  • GSK Investigational Site
    Middlesborough, TS4 3BW, United Kingdom
  • GSK Investigational Site
    Sheffield, S10 2JF, United Kingdom
10

References and documents

Publications

  • Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010 Sep;55(1):49-57. doi: 10.1097/QAI.0b013e3181dd911e. PubMed 20431394 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Oct 25, 2007
Start
Jun 2007
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Oct 15, 2010
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00549198
Lead sponsor
GlaxoSmithKline
First posted
Oct 25, 2007
Start date
Jun 2007
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Oct 15, 2010
Last update
Apr 12, 2011

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abacavir · Lamivudine · Efavirenz

Start the discussion